Full Press Release Details
Named 2016 Technology Pioneer by the World Economic Forum
NEW YORK--(BUSINESS WIRE)--June 27, 2016--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS),
a biopharmaceutical company focused on developing immunotherapies based
on gene edited CAR T-cells (UCART), today announced that the Company has
been selected as a 2016 World Economic Forum Technology Pioneer, a
credential that is awarded annually to the most innovative and impactful
companies developing new technologies around the world.
Cellectis' selection was based on its contribution to and impact on the
global healthcare and life sciences industries via the Company's
development and therapeutic application of allogeneic CAR T-cell
immunotherapies targeting cancer. In this process, T-cells from healthy
donors are genetically edited with Cellectis' proprietary TALEN
technology to seek and destroy cancer cells.
In late 2015 and early 2016, two groundbreaking compassionate care cases
have been reported with UCART19, an "off-the-shelf" gene edited T-cell
product that has been designed and manufactured by Cellectis.
"We are thrilled to be recognized for our achievements and honored to
share this title alongside other global creators, innovators, scientists
and business leaders who are constantly raising the bar with their
expertise, ideas and technologies," said Dr. Andr Choulika, Chairman
and Chief Executive Officer, Cellectis. "This collaboration, facilitated
by the World Economic Forum, is an important building block for the
future of scientific and technological breakthroughs and fits perfectly
into Cellectis' strategy of developing innovative products in an effort
to eradicate cancer."
"The World Economic Forum's Technology Pioneers community recognizes
companies from around the world that are involved in the design,
development and deployment of new technologies that are poised to have a
significant impact on business and society," said Fulvia Montresor, Head
of Technology Pioneers, World Economic Forum. "Technology Pioneers are
companies that develop and apply the most innovative and
transformational technologies in diverse fields, and the work that's
undertaken by these companies holds the promise of significantly
affecting the way that business and societies operate. Each innovation
is another step in society's attempt to harness, adapt and utilize
technology to change and improve our world."
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART). The company's
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 16 years of expertise
in genome engineering - based on its flagship TALEN
products and meganucleases and pioneering electroporation PulseAgile
technology - to create a new generation of immunotherapies. CAR
technologies are designed to target surface antigens expressed on cells.
Using its life-science-focused, pioneering genome-engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets. Cellectis is listed on
the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market
(ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it.
TALEN is a registered
trademark owned by the Cellectis Group.
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company's
objectives based on the current expectations and assumptions of the
Company's management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.
VP of Communications
Strategic Communications
Caitlin Kasunich, 212-896-1241
Harnest, 646-385-9008
VP of Corporate Strategy and Finance